Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,484 · see citing works

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,156 · see citing works

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · see citing works

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,417 · see citing works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Topp, M., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914 · see citing works

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843 · see citing works

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G. A. N., Durrant, I. J., Luger, S. M., Marks, D. I., FRANKLIN, I. M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841 · see citing works

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L., Finney, O. C., Smithers, H. M., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 751 · see citing works

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669 · see citing works

The pharmacology of second-generation chimeric antigen receptors

van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 562 · see citing works

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

van Dongen, J. J. M., van der Velden, V. H. J., Brüggemann, M., & Órfão, A. (2015) · Blood · doi:10.1182/blood-2015-03-580027 · Cited by 517 · see citing works

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H., Hüttmann, A., Kobbe, G., Kreuzer, K., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 470 · see citing works

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Theunissen, P. M. J., Mejstříková, E., Sędek, Ł., van der Sluijs‐Gelling, A. J., Gaipa, G., Bartels, M., da Costa, E. S., Kotrová, M., Nováková, M., Sonneveld, E., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726307 · Cited by 447 · see citing works

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 404 · see citing works

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S. M., Bórquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316 · see citing works

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

Tavernier, E., Boiron, J., Huguet, F., Bradstock, K. F., Vey, N., Kovacsovics, T. J., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256 · see citing works

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150 · see citing works

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

Kantarjian, H. M., Thomas, D. A., Ravandi, F., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Pierce, S. A., Shan, J., Cortes, J. E., & O'Brien, S. M. (2010) · Cancer · doi:10.1002/cncr.25354 · Cited by 124 · see citing works

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Gökbuget, N., Zugmaier, G., Klinger, M., Kufer, P., Stelljes, M., Viardot, A., Horst, H. A., Neumann, S., Brüggemann, M., Ottmann, O. G., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.153957 · Cited by 87 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675 · see citing works

CAR-T cell therapy: current limitations and potential strategies

Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926 · see citing works

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217 · see citing works

Development of therapeutic antibodies for the treatment of diseases

Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,106 · see citing works

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · see citing works

Cytokine release syndrome

Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,673 · see citing works

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works

Long-term outcomes following CAR T cell therapy: what we know so far

Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,423 · see citing works

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · see citing works

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · see citing works

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,238 · see citing works

Tumor Antigen Escape from CAR T-cell Therapy

Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,201 · see citing works

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Mackensen, A., Müller, F., Mougiakakos, D., Boeltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simón, D., Kleyer, A., Munoz, L. E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,138 · see citing works

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,133 · see citing works

Senolytic CAR T cells reverse senescence-associated pathologies

Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098 · see citing works

Clinical implications of T cell exhaustion for cancer immunotherapy

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · see citing works

Mechanisms of resistance to CAR T cell therapy

Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 986 · see citing works

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942 · see citing works

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Brudno, J. N., & Kochenderfer, J. N. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 909 · see citing works

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · see citing works

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V. V., Mastroianni, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 849 · see citing works

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 837 · see citing works

Acute lymphoblastic leukaemia

Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 795 · see citing works

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 784 · see citing works

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 753 · see citing works

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 671 · see citing works

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention

Lennon, A. M., Buchanan, A. H., Kinde, I., Warren, A., Honushefsky, A. M., Cohain, A. T., Ledbetter, D. H., Sanfilippo, F. P., Sheridan, K. M., Rosica, D., et al. (2020) · Science · doi:10.1126/science.abb9601 · Cited by 665 · see citing works

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla‐Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1054-1 · Cited by 664 · see citing works

T cell-engaging therapies — BiTEs and beyond

Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 658 · see citing works

Non-genetic mechanisms of therapeutic resistance in cancer

Marine, J., Dawson, S., & Dawson, M. A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 658 · see citing works

Clinical lessons learned from the first leg of the CAR T cell journey

Majzner, R. G., & Mackall, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0564-6 · Cited by 636 · see citing works

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Ghorashian, S., Kramer, A. M., Onuoha, S. C., Wright, G., Bartram, J. L., Richardson, R., Albon, S. J., Castro, F., Popova, B., Villanueva, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0549-5 · Cited by 630 · see citing works

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Spiegel, J. Y., Patel, S., Muffly, L. S., Hossain, N. M., Oak, J. S., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01436-0 · Cited by 624 · see citing works

An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer

Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25418 · Cited by 614 · see citing works

Metabolic barriers to cancer immunotherapy

DePeaux, K., & Delgoffe, G. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00541-y · Cited by 614 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Tuning the Antigen Density Requirement for CAR T-cell Activity

Majzner, R. G., Rietberg, S. P., Sotillo, E., Dong, R., Vachharajani, V. T., Labanieh, L., Myklebust, J. H., Kadapakkam, M., Weber, E. W., Tousley, A. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0945 · Cited by 580 · see citing works

Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome

Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax7969 · Cited by 566 · see citing works

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Daver, N. G., Garcia‐Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M. Y., Ravandi‐Kashani, F., Jabbour, E. J., Kadia, T. M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 562 · see citing works

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Suhoski, M. M., Hwang, W., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 548 · see citing works

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547 · see citing works

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531 · see citing works

Targeting Cancer Stemness in the Clinic: From Hype to Hope

Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517 · see citing works

Immunosenescence: a key player in cancer development

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N. C., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 494 · see citing works

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

Schubert, M., Schmitt, M. W., Wang, L., Ramos, C. A., Jordan, K., Müller‐Tidow, C., & Dreger, P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 493 · see citing works

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

Salter, A. I., Ivey, R. G., Kennedy, J. J., Voillet, V., Rajan, A., Alderman, E. J., Voytovich, U. J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat6753 · Cited by 486 · see citing works

Engineering and Design of Chimeric Antigen Receptors

Guedan, S., Calderón, H., Posey, A. D., & Maus, M. V. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 452 · see citing works

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.022 · Cited by 451 · see citing works

In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo

Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 448 · see citing works

CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T cell potency and toxicity: updated results from a phase I anti-CD22 CAR T cell trial

Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421 · see citing works

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 416 · see citing works

GPRC5D-Targeted CAR T Cells for Myeloma

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209900 · Cited by 411 · see citing works

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Hay, K. A., Gauthier, J., Hirayama, A. V. V., Voutsinas, J. M., Wu, Q. V., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood · doi:10.1182/blood-2018-11-883710 · Cited by 407 · see citing works

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

Frey, N. V., & Porter, D. L. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.756 · Cited by 406 · see citing works

Organoid Models of Tumor Immunology

Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 401 · see citing works

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 395 · see citing works

γδ T cells: origin and fate, subsets, diseases and immunotherapy

Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 395 · see citing works

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391 · see citing works

Emerging Cellular Therapies for Cancer

Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 386 · see citing works

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci‐Danicar, O., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32334-5 · Cited by 376 · see citing works

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub‐Agha, I., Chabannon, C., Bader, P., Basak, G. W., Bonig, H. B., Ciceri, F., Corbacioglu, S., Duarte, R. F., Einsele, H., Hudecek, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.229781 · Cited by 371 · see citing works

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Dimitri, A. J., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 370 · see citing works

Targeting a neoantigen derived from a common <i>TP53</i> mutation

Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367 · see citing works

Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition

Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 357 · see citing works

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Shah, N. N., Lee, D. W., Yates, B., Yuan, C. M., Shalabi, H., Martin, S. C., Wolters, P. L., Steinberg, S. M., Baker, E. H., Delbrook, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02262 · Cited by 356 · see citing works

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Karschnia, P., Jordan, J. T., Forst, D. A., Arrillaga‐Romany, I., Batchelor, T. T., Baehring, J. M., Clement, N. F., Castro, L. N. G., Herlopian, A., Maus, M. V., et al. (2019) · Blood · doi:10.1182/blood-2018-12-893396 · Cited by 355 · see citing works

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 351 · see citing works

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349 · see citing works

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0272 · Cited by 349 · see citing works

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 343 · see citing works

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 341 · see citing works

CAR-T cell therapy for cancer: current challenges and future directions

Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 332 · see citing works

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Baumeister, S. H. C., Murad, J., Werner, L. L., Daley, H., Trebeden‐Negre, H., Gicobi, J. K., Schmucker, A. C., Reder, J., Sentman, C. L., Gilham, D. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0307 · Cited by 331 · see citing works

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, C., Wang, Z.-L., Xu, T., He, Z., & Wei, Y.-Q. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 331 · see citing works

The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden

Santomasso, B., Bachier, C. R., Westin, J. R., Rezvani, K., & Shpall, E. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238691 · Cited by 330 · see citing works

Current understanding and management of CAR T cell-associated toxicities

Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 330 · see citing works

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Dai, H., Wu, Z., Jia, H., Tong, C., Guo, Y., Ti, D., Han, X., Liu, Y., Zhang, W., Wang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00856-8 · Cited by 329 · see citing works

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 326 · see citing works

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations

Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324 · see citing works

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

Kotch, C., Barrett, D. M., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 322 · see citing works

Understanding and treating the inflammatory adverse events of cancer immunotherapy

Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319 · see citing works

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 319 · see citing works

Universal CARs, universal T cells, and universal CAR T cells

Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 315 · see citing works

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Cappell, K. M., Sherry, R. M., Yang, J. C.-H., Goff, S. L., Vanasse, D., McIntyre, L. S., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 311 · see citing works

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas

Ramos, C. A., Rouce, R. H., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., Mehta, B., Zhang, H., Dakhova, O., Carrum, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.009 · Cited by 300 · see citing works

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2024) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 300 · see citing works

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction

Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295 · see citing works

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases

Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 295 · see citing works

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 287 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C. A., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 282 · see citing works

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Curran, K. J., Margossian, S. P., Kernan, N. A., Silverman, L. B., Williams, D. A., Shukla, N. N., Kobos, R., Forlenza, C. J., Steinherz, P. G., Prockop, S. E., et al. (2019) · Blood · doi:10.1182/blood.2019001641 · Cited by 278 · see citing works

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma

Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020) · Blood · doi:10.1182/blood.2020005278 · Cited by 274 · see citing works

NK cells and ILCs in tumor immunotherapy

Sivori, S., Pende, D., Quatrini, L., Pietra, G., Chiesa, M. D., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 273 · see citing works

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E. C., Gill, S. I., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01892 · Cited by 272 · see citing works

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Jain, T., Knežević, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M. M., Shah, G. L., Halton, E. F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002509 · Cited by 272 · see citing works

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Enblad, G., Karlsson, H., Gammelgård, G., Wenthe, J., Lövgren, T., Amini, R., Wikstrom, K. I., Essand, M., Savoldo, B., Hallböök, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0426 · Cited by 269 · see citing works

Abstract CT078: Impact of disease burden and transplant on long-term survival after CD19 CAR therapy in adults with relapsed B-cell acute lymphoblastic leukemia

Park, J. H., Rivere, I., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C. S., Wang, Y., Santomasso, B., Li, D., Brentjens, R. J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct078 · Cited by 4 · see citing works

Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.

Park, J. H., Rivière, I., Wang, X., Sénéchal, B., Wang, Y., Mead, E., Santomasso, B., Halton, E. F., Diamonte, C., Bernal, Y. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7008 · Cited by 17 · see citing works

Parameters of long‐term response with CD28 ‐based CD19 chimaeric antigen receptor‐modified T cells in children and young adults with B‐acute lymphoblastic leukaemia

Jacoby, E., Bielorai, B., Hutt, D., Itzhaki, O., Adam, E., Bar, D., Besser, M. J., & Toren, A. (2022) · British Journal of Haematology · doi:10.1111/bjh.18105 · Cited by 26 · see citing works

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Zhang, X., Yang, J., Li, W., Zhang, G., Su, Y., Shi, Y., Song, D., Zhang, M., He, J., Xu, L., et al. (2020) · Blood · doi:10.1182/blood-2020-136897 · Cited by 4 · see citing works

Factors Associated with Survival and Severe Cytokine Release Syndrome of Patients with Relapsed/Refractory B-ALL Receiving CD19 CAR-T Cell Therapy

Li, X., Luo, C., Xu, S., Ma, Y., & Chen, J. (2020) · Blood · doi:10.1182/blood-2020-139254